Immunodominance of AML neoantigens, ranked by the number of responding donors and IFN-γ ELISpot response
| Mutation . | Responding donors, n (%) . | Mean ± SEM . | Median (range) . |
|---|---|---|---|
| IDH2R140Q | 11 (65%) | 391 ± 92 | 286 (770-31) |
| IDH1R132H | 7 (41%) | 295 ± 106 | 115 (796-58) |
| FLT3D835Y | 6 (35%) | 242 ± 87 | 161.5 (642-85) |
| DNMT3AR882H | 5 (29%) | 69 ± 16 | 64 (111-35) |
| NPM1 types A, D | 3 (18%) | 173 ± 29 | 152 (230-138) |
| NPM1 type B | 3 (18%) | 76 ± 22 | 87 (107-35) |
| KRASG12A | 3 (18%) | 304 ± 84 | 303.5 (387-220) |
| KRASG12V | 3 (18%) | 42 ± 4 | 38 (51-38) |
| DNMT3AR882C | 2 (12%) | 36 ± 0 | 36 (36-36) |
| NRASQ61K | 1 (6%) | 229 ± 0 | 229 (229-229) |
| KRASG12D | 1 (6%) | 55 ± 0 | 55 (55-55) |
| JAK2V617F | 1 (6%) | 45 ± 0 | 45 (45-45) |
| KRASG13D | 0 (0%) | - | - |
| NRASQ61R | 0 (0%) | - | - |
| Mutation . | Responding donors, n (%) . | Mean ± SEM . | Median (range) . |
|---|---|---|---|
| IDH2R140Q | 11 (65%) | 391 ± 92 | 286 (770-31) |
| IDH1R132H | 7 (41%) | 295 ± 106 | 115 (796-58) |
| FLT3D835Y | 6 (35%) | 242 ± 87 | 161.5 (642-85) |
| DNMT3AR882H | 5 (29%) | 69 ± 16 | 64 (111-35) |
| NPM1 types A, D | 3 (18%) | 173 ± 29 | 152 (230-138) |
| NPM1 type B | 3 (18%) | 76 ± 22 | 87 (107-35) |
| KRASG12A | 3 (18%) | 304 ± 84 | 303.5 (387-220) |
| KRASG12V | 3 (18%) | 42 ± 4 | 38 (51-38) |
| DNMT3AR882C | 2 (12%) | 36 ± 0 | 36 (36-36) |
| NRASQ61K | 1 (6%) | 229 ± 0 | 229 (229-229) |
| KRASG12D | 1 (6%) | 55 ± 0 | 55 (55-55) |
| JAK2V617F | 1 (6%) | 45 ± 0 | 45 (45-45) |
| KRASG13D | 0 (0%) | - | - |
| NRASQ61R | 0 (0%) | - | - |
SEM, standard error of the mean.